Currently, there are 14.01M common shares owned by the public and among those 7.84M shares have been available to trade.
The company’s stock has a 5-day price change of 16.59% and 103.82% over the past three months. CPIX shares are trading 12.66% year to date (YTD), with the 12-month market performance up to 25.94% higher. It has a 12-month low price of $1.04 and touched a high of $3.05 over the same period. CPIX has an average intraday trading volume of 1.85 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.79%, 56.30%, and 76.52% respectively.
Institutional ownership of Cumberland Pharmaceuticals Inc (NASDAQ: CPIX) shares accounts for 14.55% of the company’s 14.01M shares outstanding.
It has a market capitalization of $37.49M and a beta (3y monthly) value of 0.13. The earnings-per-share (ttm) stands at -$0.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.57% over the week and 13.48% over the month.
Analysts forecast that Cumberland Pharmaceuticals Inc (CPIX) will achieve an EPS of 0 for the current quarter, 0 for the next quarter and 0 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0 while analysts give the company a high EPS estimate of 0. Comparatively, EPS for the current quarter was 0.02 a year ago.
Looking at the support for the CPIX, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on November 12, 2012, with the firm’s price target at $6.50-$5. UBS coverage for the Cumberland Pharmaceuticals Inc (CPIX) stock in a research note released on February 01, 2011 offered a Neutral rating with a price target of $6.50. UBS was of a view on December 16, 2010 that the stock is Neutral, while UBS gave the stock Buy rating on August 17, 2010, issuing a price target of $11- $10. Morgan Joseph on their part issued Buy rating on August 17, 2010.
